Potent inhibition of human enterovirus 71 replication by type I interferon subtypes

Antiviral Therapy

Volumn 16, Issue 1, 2011, Pages 51-58

  Yi, Lina ^a   He, Yaqing ^b   Chen, Ying ^a   Kung, Hsiang Fu ^a,c   He, Ming Liang ^a,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA INTERFERON 4; ALPHA INTERFERON 6; ALPHA14 INTERFERON; ALPHA16 INTERFERON; ALPHA2A INTERFERON; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG POTENCY; ENTEROVIRUS 71; GENE EXPRESSION PROFILING; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; VERO CELL; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; CERCOPITHECUS AETHIOPS; CYTOPATHOGENIC EFFECT, VIRAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROVIRUS A, HUMAN; ENTEROVIRUS INFECTIONS; GENE EXPRESSION; HUMANS; INTERFERON TYPE I; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; VERO CELLS; VIRUS REPLICATION;

EID: 79951490572     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: 10.3851/IMP1720     Document Type: Article

References (33)

1. Huang YP, Lin TL, Kuo CY, et al. The circulation of subgenogroups B5 and C5 of enterovirus 71 in Taiwan from 2006 to 2007. Virus Res 2008; 137:206-212.
2. Ang LW, Koh BK, Chan KP, Chua LT, James L, Goh KT. Epidemiology and control of hand, foot and mouth disease in Singapore, 2001-2007. Ann Acad Med Singapore 2009; 38:106-112.
3. Ortner B, Huang CW, Schmid D, et al. Epidemiology of enterovirus types causing neurological disease in Austria 1999-2007: detection of clusters of echovirus 30 and enterovirus 71 and analysis of prevalent genotypes. J Med Virol 2009; 81:317-324.
4. AbuBakar S, Sam IC, Yusof J, et al. Enterovirus 71 outbreak, Brunei. Emerg Infect Dis 2009; 15:79-82.
5. Schmidt NJ, Lennette EH, Ho HH. An apparently new enterovirus isolated from patients with disease of the central nervous system. J Infect Dis 1974; 129:304-309.
6. Fowlkes AL, Honarmand S, Glaser C, et al. Enterovirus-associated encephalitis in the California encephalitis project, 1998-2005. J Infect Dis 2008; 198:1685-1691.
7. Hamaguchi T, Fujisawa H, Sakai K, et al. Acute encephalitis caused by intrafamilial transmission of enterovirus 71 in adult. Emerg Infect Dis 2008; 14:828-830. (Pubitemid 351838655)
8. Bible JM, Pantelidis P, Chan PK, Tong CY. Genetic evolution of enterovirus 71: epidemiological and pathological implications. Rev Med Virol 2007; 17:371-379. (Pubitemid 350144562)
9. Tseng FC, Huang HC, Chi CY, et al. Epidemiological survey of enterovirus infections occurring in Taiwan between 2000 and 2005: analysis of sentinel physician surveillance data. J Med Virol 2007; 79:1850-1860.
10. Ooi MH, Wong SC, Mohan A, et al. Identification and validation of clinical predictors for the risk of neurological involvement in children with hand, foot, and mouth disease in Sarawak. BMC Infect Dis 2009; 9:3.
11. Lin TY, Chang LY, Hsia SH, et al. The 1998 enterovirus 71 outbreak in Taiwan: pathogenesis and management. Clin Infect Dis 2002; 34 Suppl 2:S52-S57.
12. Ding NZ, Wang XM, Sun SW, Song Q, Li SN, He CQ. Appearance of mosaic enterovirus 71 in the 2008 outbreak of China. Virus Res 2009; 145:157-161.
13. Brown BA, Oberste MS, Alexander JP, Jr., Kennett ML, Pallansch MA. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol 1999; 73:9969-9975.
14. Chung YC, Ho MS, Wu JC, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine 2008; 26:1855-1862.
15. Foo DG, Ang RX, Alonso S, Chow VT, Quak SH, Poh CL. Identification of immunodominant VP1 linear epitope of enterovirus 71 (EV71) using synthetic peptides for detecting human anti-EV71 IgG antibodies in western blots. Clin Microbiol Infect 2008; 14:286-288. (Pubitemid 351201022)
16. Arita M, Wakita T, Shimizu H. Characterization of pharmacologically active compounds that inhibit poliovirus and enterovirus 71 infectivity. J Gen Virol 2008; 89:2518-2530.
17. Li ZH, Li CM, Ling P, et al. Ribavirin reduces mortality in enterovirus 71-infected mice by decreasing viral replication. J Infect Dis 2008; 197:854-857. (Pubitemid 351417008)
18. Choi HJ, Lim CH, Song JH, Baek SH, Kwon DH. Antiviral activity of raoulic acid from Raoulia australis against Picornaviruses. Phytomedicine 2009; 16:35-39.
19. Vilcek J. Novel interferons. Nat Immunol 2003; 4:8-9. (Pubitemid 36104699)
20. Parmar S, Platanias LC. Interferons: mechanisms of action and clinical applications. Curr Opin Oncol 2003; 15:431-439. (Pubitemid 38147038)
21. Pestka S, Krause CD, Walter MR. Interferons, interferon-like cytokines, and their receptors. Immunol Rev 2004; 202:8-32. (Pubitemid 39576902)
22. Jaks E, Gavutis M, Uze G, Martal J, Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007; 366:525-539. (Pubitemid 46136210)
23. Sozzani S, Bosisio D, Scarsi M, Tincani A. Type I interferons in systemic autoimmunity. Autoimmunity 2010; 43:196-203.
24. Takaoka A, Yanai H. Interferon signalling network in innate defence. Cell Microbiol 2006; 8:907-922. (Pubitemid 43670834)
25. Sadler AJ, Williams BR. Interferon-inducible antiviral effectors. Nat Rev Immunol 2008; 8:559-568. (Pubitemid 351913674)
26. Chu CJ, Lee SD. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol 2008; 23:512-520.
27. Palumbo E. PEG-interferon in acute and chronic hepatitis C: a review. Am J Ther 2009; 16:573-578.
28. Karber G. End-point calulation. Arch Exp Pathol Pharmak 1931; 162:480-483.
29. Ho HY, Cheng ML, Weng SF, et al. Glucose-6-phosphate dehydrogenase deficiency enhances enterovirus 71 infection. J Gen Virol 2008; 89:2080-2089.
30. Liu ML, Lee YP, Wang YF, et al. Type I interferons protect mice against enterovirus 71 infection. J Gen Virol 2005; 86:3263-3269.
31. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006; 6:836-848. (Pubitemid 44631652)
32. Meurs EF, Breiman A. The interferon inducing pathways and the hepatitis C virus. World J Gastroenterol 2007; 13:2446-2454. (Pubitemid 46929500)
33. de Weerd NA, Samarajiwa SA, Hertzog PJ. Type I interferon receptors: biochemistry and biological functions. J Biol Chem 2007; 282:20053-20057. (Pubitemid 47099976)